Given that both types of DM are characterized by chronic inflammation and disturbances in the immune system, inhibiting the nuclear factor kappa-light-chain-enhancer of the activated B cells (NF-κB) signaling pathway could mitigate some of the foundational processes of the disease. The gene discussed is NFKB1; the disease is diabetes mellitus.